Newly Diagnosed Multiple Myeloma, Response, Bone Health, Renal Health, MRD, Survivorship Care
(click on the image above to view the video)
This video was recorded at the IMF Satellite Symposium that took place at the April 2019 Oncology Nursing Society’s annual meeting. It is the second in a three-part series on myeloma nursing. In this segment, Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN (Taussig Cancer Insitute, Cleveland Clinic - Cleveland) and Sandra Rome RN, MN, AOCN, CNS discuss newly diagnosed multiple myeloma, response, bone health, renal health, minimal residual disease, survivorship care, relapsed myeloma, multiple therapeutic options, and immunotherapy considerations.
- Multiple Myeloma Background, Shared Decision Making, and Smoldering MM Research Update
- Newly Diagnosed Multiple Myeloma, Response, Bone Health, Renal Health, MRD, Survivorship Care
- Relapsed Myeloma, Treatment for Relapsed Myeloma, Drugs in Development, Knowledge Post-Test
This activity is supported by educational grants provided by Takeda Oncology, Celgene Corporation, Karyopharm Therapeutics Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.